Amorfix appoints Ms. Meryl J. Chertoff to its Board of Directors

TSX: AMF

TORONTO, Sept. 9, 2011 /CNW/ - Amorfix Life Sciences, a product development company focused on diagnostics and therapeutics for misfolded protein diseases, today announced that it has appointed Ms. Meryl J. Chertoff, Director of The Aspen Institute's Justice and Society Program and Adjunct Professor of Law at Georgetown Law, to its Board of Directors

Ms. Chertoff's legal career includes senior roles at various high profile government offices and agencies.  She is a leader in educational programs regarding the US Federal and State courts.  She served in the Office of Legislative Affairs at the Federal Emergency Management Agency (FEMA), participating in the agency's transition into the Department of Homeland Security in 2003. Ms. Chertoff has also been a legislative relations professional, Director of New Jersey's Washington, D.C. Office under two governors, and legislative counsel to the Chair of the New Jersey State Assembly Appropriations Committee. She served on the Board of the Anti-Defamation League of New Jersey, and chaired its civil rights committee.  She was Director of the Sandra Day O'Connor Project on the State of the Judiciary at Georgetown Law, studying and educating the public about federal and state courts. At Georgetown Law, she also developed educational programs for visiting judges and other government officials from overseas.  Ms. Chertoff is a magna cum laude graduate of Harvard-Radcliffe College and earned her J.D. from Harvard Law School.

In addition to work at the Aspen Institute and Georgetown Law, Ms. Chertoff is a member of the O'Connor Judicial Selection Initiative Advisory Committee at the Institute for the Advancement of the American Legal System at the University of Denver; a member of the Washington Area Advisory Committee of Common Sense Media; and a Trustee of the Meridian International Center in Washington, DC, where she chairs the Arts Advisory Committee.

Philippe Couillard, Chairman of the Amorfix Board of Directors, commented, "We are very pleased to welcome Ms. Chertoff to the Company's Board.  Ms. Chertoff's legal expertise, committee experience and other impressive qualifications will be a great addition to our Board of Directors."

About Amorfix
www.amorfix.com.

Amorfix Life Sciences Ltd. (TSX: AMF) is a product development company developing therapeutic products and diagnostic devices targeting misfolded protein diseases including Alzheimer's Disease (AD), cancers, and ALS. Amorfix utilizes its computational discovery platform, ProMIS™, to predict novel Disease Specific Epitopes ("DSEs") on the molecular surface of misfolded proteins. Amorfix's lead programs include therapeutics and companion diagnostics for cancers, antibodies and vaccines to DSEs in ALS and AD diagnostic tests. In addition, Amorfix's proprietary Epitope Protection™ technology enables it to specifically identify very low levels of misfolded proteins in a biological sample. The Company's diagnostic programs include an ultrasensitive method for the detection of aggregated beta-Amyloid in brain tissue, CSF and blood from animal models of AD, months prior to observable amyloid formation, and development of a human screening test for AD. For more information about Amorfix, visit www.amorfix.com.

The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release may contain certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company's current beliefs as well as assumptions made by and information currently available to it as well as other factors.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE Amorfix Life Sciences Ltd.

For further information:

Dr. Robert Gundel
President and Chief Executive Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6957
Fax: (416) 847-6899
bob.gundel@amorfix.com
                Janet Clennett
Acting Chief Financial Officer
Amorfix Life Sciences Ltd.
Tel: (416) 847-6926
Fax: (416) 847-6899
Janet.clennett@amorfix.com

 

Profil de l'entreprise

Amorfix Life Sciences Ltd.

Renseignements sur cet organisme


FORFAITS PERSONNALISÉS

Jetez un coup d’œil sur nos forfaits personnalisés ou créez le vôtre selon vos besoins de communication particuliers.

Commencez dès aujourd'hui .

ADHÉSION À CNW

Remplissez un formulaire d'adhésion à CNW ou communiquez avec nous au 1-877-269-7890.

RENSEIGNEZ-VOUS SUR LES SERVICES DE CNW

Demandez plus d'informations sur les produits et services de CNW ou communiquez avec nous au 1‑877-269-7890.